Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
AbstractBackground. Activating mutations in the pathway of phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) occur in 43-70% of bre
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
07 June 2019
|
| In: |
Neuro-Oncology
Year: 2019, Volume: 21, Issue: 11, Pages: 1401-1411 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noz105 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1093/neuonc/noz105 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/21/11/1401/5512506 
|
| Author Notes: | Franziska Maria Ippen, Julia Katharina Grosch, Megha Subramanian, Benjamin Macfarlane Kuter, Bianca M. Liederer, Emile G. Plise, Joana Liliana Mora, Naema Nayyar, Stephen Paul Schmidt, Anita Giobbie-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, and Priscilla Kaliopi Brastianos |
| Summary: | AbstractBackground. Activating mutations in the pathway of phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) occur in 43-70% of bre |
|---|---|
| Item Description: | Gesehen am 30.01.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noz105 |